Epigenome-Wide Association Studies Provide Insight into the Pathogenesis of Non-alcoholic Fatty Liver Disease and Non-alcoholic Steatohepatitis

被引：6
|
作者：
Birerdinc, Aybike [2 ]
Younossi, Zobair M. [1 ,2 ]
机构：
[1] Inova Fairfax Hosp, Dept Med & Ctr Liver Dis, Falls Church, VA USA
[2] Inova Hlth Syst, Betty & Guy Beatty Ctr Integrated Res, Falls Church, VA 22042 USA
来源：
ANNALS OF HEPATOLOGY | 2018年 / 17卷 / 01期
关键词：
NASH; NAFLD; EWAS; UNITED-STATES; FERROPTOSIS; EPIDEMIOLOGY; FIBROSIS;
D O I：
10.5604/01.3001.0010.7530
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
Non-alcoholic Fatty Liver Disease (NAFLD) and its progressive form or NASH with fibrosis, are rapidly increasing in conjunction with the growing rates of obesity and type II diabetes. Novel technologies such as epigenome-wide association studies (EWAS) may provide opportunities to get valuable insight into not only the mechanisms of disease, but to also discover potential biomarker targets with clinical relevance to disease stage.
引用
收藏
页码：11 / 13
页数：3
相关论文
共 50 条
  • [41] Clinical Predictors of Recurrent Non-Alcoholic Steatohepatitis Following Liver Transplantation for Non-Alcoholic Fatty Liver Disease
    Stein, L.
    Dunn, W.
    Nguyen, H.
    Bhasin, D.
    Pollinger, H.
    Johnson, M.
    Shrestha, R.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2014, 14 : 703 - 703
  • [42] Diagnosis of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis: Non-invasive tests are enough
    Castera, Laurent
    LIVER INTERNATIONAL, 2018, 38 : 67 - 70
  • [43] Beneficial effect of omarigliptin on diabetic patients with non-alcoholic fatty liver disease/non-alcoholic steatohepatitis
    Sachiko Hattori
    Kazuomi Nomoto
    Tomohiko Suzuki
    Seishu Hayashi
    Diabetology & Metabolic Syndrome, 13
  • [44] Beneficial effect of omarigliptin on diabetic patients with non-alcoholic fatty liver disease/non-alcoholic steatohepatitis
    Hattori, Sachiko
    Nomoto, Kazuomi
    Suzuki, Tomohiko
    Hayashi, Seishu
    DIABETOLOGY & METABOLIC SYNDROME, 2021, 13 (01):
  • [45] Targeting Kupffer cells in non-alcoholic fatty liver disease/non-alcoholic steatohepatitis: Why and how?
    Lanthier, Nicolas
    WORLD JOURNAL OF HEPATOLOGY, 2015, 7 (19) : 2184 - 2188
  • [46] UNDERSTANDING RISK FOR NON-ALCOHOLIC STEATOHEPATITIS AND NON-ALCOHOLIC FATTY LIVER DISEASE IN MEDICARE AND MEDICAID CLAIMS
    Nelson, Katherine
    Gellar, Jonathan
    Anderson, Ryan Taylor
    Campbell, Patrick
    Chen, Arnold
    HEPATOLOGY, 2023, 78 : S2146 - S2147
  • [47] Multiparametric MR Index for the Diagnosis of Non-Alcoholic Steatohepatitis in Patients with Non-Alcoholic Fatty Liver Disease
    Jeong Woo Kim
    Young-Sun Lee
    Yang Shin Park
    Baek-Hui Kim
    Soo Yeon Lee
    Jong Eun Yeon
    Chang Hee Lee
    Scientific Reports, 10
  • [48] Navigating the Link Between Non-alcoholic Fatty Liver Disease/ Non-alcoholic Steatohepatitis and Cardiometabolic Syndrome
    Gato, Sheila
    Garcia-Fernandez, Vanessa
    Gil-Gomez, Antonio
    Rojas, Angela
    Montero-Vallejo, Rocko
    Munoz-Hernandez, Rocko
    Romero-Gomez, Manuel
    EUROPEAN CARDIOLOGY REVIEW, 2024, 19
  • [49] Non-alcoholic Fatty Liver Disease (NAFLD) and non-alcoholic Steatohepatitis (NASH): Pathophysiology and Nutritional Aspects
    Schattenberg, Joern M.
    ERNAHRUNGS UMSCHAU, 2015, 62 (02): : M92 - M100
  • [50] Unlocking the Therapeutic Potential of Ellagic Acid for Non-Alcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis
    Senavirathna, Tharani
    Shafaei, Armaghan
    Lareu, Ricky
    Balmer, Lois
    ANTIOXIDANTS, 2024, 13 (04)
12345